Blog
CJC-1295 (No DAC)
Definition
CJC-1295 (No DAC) is a synthetic peptide analogue of growth hormone–releasing hormone (GHRH). In research environments, it is studied for its ability to stimulate endogenous growth hormone signaling through pituitary-related pathways without long-acting albumin binding modifications.
Chemical Structure
CJC-1295 (No DAC) is a 29–amino acid peptide closely related to native GHRH (1–29). Unlike DAC-modified versions, it lacks chemical linkers for albumin binding, resulting in a shorter active profile useful for pulsatile signaling studies.
FAQs
1. What is CJC-1295 (No DAC) studied for?
Researchers study it to understand growth hormone release dynamics and pituitary signaling mechanisms.
2. How does CJC-1295 (No DAC) differ from DAC versions?
The No DAC version lacks long-acting modifications, allowing shorter observation windows in studies.
3. Is CJC-1295 (No DAC) naturally occurring?
It is a synthetic analogue based on a naturally occurring hormone fragment.
4. Is CJC-1295 (No DAC) FDA approved?
No. It is sold by ChRIS Peptides strictly for research use only.
5. Why is pulsatile signaling important in research?
Pulsatile hormone release more closely mimics physiological signaling patterns.
6. Is CJC-1295 (No DAC) a growth hormone?
No. It stimulates signaling upstream of growth hormone release rather than acting as GH itself.
7. Does ChRIS Peptides provide dosing protocols?
No. ChRIS Peptides does not provide usage or dosing instructions.
8. Can research results vary with CJC-1295 (No DAC)?
Yes. Outcomes depend on experimental design and model systems.
9. Is CJC-1295 (No DAC) a pharmaceutical?
No. It is not sold as a medication or therapeutic.
10. Why is CJC-1295 (No DAC) used in endocrine research?
Its structure supports controlled studies of hormone signaling without prolonged exposure.
